236 related articles for article (PubMed ID: 16964835)
1. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Wursthorn K; Buggisch P; Lutgehetmann M; Zollner B; Petersen J
Antivir Ther; 2006; 11(5):647-52. PubMed ID: 16964835
[TBL] [Abstract][Full Text] [Related]
2. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Ingiliz P; Valantin MA; Thibault V; Duvivier C; Dominguez S; Katlama C; Poynard T; Benhamou Y
Antivir Ther; 2008; 13(7):895-900. PubMed ID: 19043923
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
5. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
[TBL] [Abstract][Full Text] [Related]
6. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Soriano V; Tuma P; Vispo E; Labarga P; Fernández JV; Medrano J; Barreiro P
J HIV Ther; 2009 Mar; 14(1):13-8. PubMed ID: 19731560
[TBL] [Abstract][Full Text] [Related]
9. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
Yaşar DG; Suyanı E; Özenirler S; Sucak GT
Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
[TBL] [Abstract][Full Text] [Related]
10. Successful interferon treatment in a patient chronically infected with hepatitis B virus carrying unusual S- (and P-) mutants in the presence of anti-HBs antibodies.
Frider B; Alessio A; Pozzati M; Cuestas ML; Mathet VL; Oubiña JR
Liver Int; 2007 Jun; 27(5):727-30. PubMed ID: 17498261
[TBL] [Abstract][Full Text] [Related]
11. Variability in long-term hepatitis B virus dynamics under antiviral therapy.
Murray JM; Stancevic O; Lütgehetmann M; Wursthorn K; Petersen J; Dandri M
J Theor Biol; 2016 Feb; 391():74-80. PubMed ID: 26723531
[TBL] [Abstract][Full Text] [Related]
12. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM
J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
[TBL] [Abstract][Full Text] [Related]
13. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F
J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127
[TBL] [Abstract][Full Text] [Related]
14. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.
Boyd A; Canini L; Gozlan J; Lascoux-Combe C; Miailhes P; Fonquernie L; Girard PM; Lacombe K
J Clin Virol; 2017 Oct; 95():55-60. PubMed ID: 28869890
[TBL] [Abstract][Full Text] [Related]
15. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
16. Treatment of HIV/HBV coinfection: clinical and virologic issues.
Thio CL; Locarnini S
AIDS Rev; 2007; 9(1):40-53. PubMed ID: 17474312
[TBL] [Abstract][Full Text] [Related]
17. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
18. Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.
Cortez KJ; Proschan MA; Barrett L; Brust DG; Weatherley B; Formentini E; Davey RT; Masur H; Polis MA; Neumann And AU; Kottilil S
HIV Clin Trials; 2013; 14(4):149-59. PubMed ID: 23924587
[TBL] [Abstract][Full Text] [Related]
19. [A cross-sectional survey of occult hepatitis B virus infection in HIV-infected patients].
Ma JX; Lu HZ; Wang JR; Zhang RF; Zheng YF; Liu L; Qi TK; Shen YZ
Zhonghua Nei Ke Za Zhi; 2008 Jul; 47(7):574-7. PubMed ID: 19035170
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].
Zhang RF; Liu L; Zheng YF; Shen YZ; Chen J; Gu SM; Wang JR; Lu HZ
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):189-91. PubMed ID: 23967739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
